Vabysmo (faricimab-svoa) / Roche, Ligand - LARVOL DELTA

Real-World Outcomes of Faricimab Versus Aflibercept in Treatment-Naïve Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment. (PubMed, Semin Ophthalmol) - "Serous component resolution was also more frequent with faricimab (100% vs 61.5%; p = .045). Both treatments improved retinal anatomy, while faricimab produced greater fibrovascular RPED height reduction and more complete serous component resolution."

Journal • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Ollin Biosciences Announces Presentations and Symposium at EURETINA 2026 (Businesswire) - "Ollin Biosciences...announced an upcoming presentation of results from its previously completed head-to-head JADE proof-of-concept clinical trial evaluating OLN324 versus faricimab (Vabysmo) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the 26th European Society of Retina Specialists (EURETINA) Annual Congress, taking place in Vienna, Austria, from October 1-4, 2026....In addition, Ollin announced a symposium on the promise of next-generation VEGF/Ang2 dual inhibition, featuring leading international ophthalmology faculty."

P1 data • Diabetic Macular Edema • Wet Age-related Macular Degeneration

Retinopathy of Prematurity in the Anti-VEGF Era: Screening Systems and Practical Treatment Decision-Making Across Anti-VEGF, Laser, and Surgery. (PubMed, Prog Retin Eye Res) - "Ranibizumab and aflibercept appear to have more reassuring systemic profiles than bevacizumab, although long-term comparative data remain limited. Faricimab and topical dexamethasone remain investigational. Future priorities include integrated screening networks, standardized retreatment algorithms, and longitudinal registries tracking ocular and developmental outcomes."

Journal • Review • Ophthalmology • Retinal Disorders • Retinopathy of Prematurity

Use of faricimab for refractory diabetic macular edema in real-world clinical practice: When anatomical success meets functional limits. (PubMed, PLoS One) - "Faricimab achieved effective retinal fluid control in both naïve and refractory DME. However, visual recovery was associated with baseline retinal microstructural integrity, with DRIL and ELM/EZ disruption independently associated with poorer 12-month visual outcomes beyond conventional anatomical parameters. In eyes with refractory DME and limited visual improvement, sustained fluid control and reduced treatment burden may remain clinically meaningful outcomes."

Journal • Real-world evidence • Retrospective data • Diabetic Macular Edema • Ophthalmology

Discordance Between Eye-Specific Clinical Outcomes and Patient-Reported Visual Function After Faricimab Treatment for Neovascular Age-Related Macular Degeneration: A Two-Case Report. (PubMed, Vision (Basel)) - "In the second case, best-corrected visual acuity improved from 20/100 to 20/45 and central retinal thickness decreased from 341 to 186 µm, whereas the National Eye Institute Visual Function Questionnaire-25 score declined from 67.08 to 33.17 and the exploratory ordinal colour-vividness rating was 75 at baseline and 25 at follow-up. Changes in patient-reported visual functioning may not always parallel conventional clinical outcomes, while the contrasting exploratory colour-vividness ratings observed in these two cases warrant further investigation."

Clinical data • Journal • Age-related Macular Degeneration • Geriatric Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Differential Remodeling of the Macular Neovascular Network under Different Anti-VEGF Agents in Age-Related Macular Degeneration. (PubMed, Ophthalmol Sci) - "A total of 120 eyes from 102 patients with nAMD treated with ranibizumab 0.5 mg every 4 weeks (n = 30), aflibercept 2.0 mg every 4 weeks (n = 30), aflibercept 8.0 mg every 12 weeks (n = 30), or faricimab 6.0 mg every 8 weeks (n = 30) in a treat-and-extend regimen. Long-term studies are needed to determine whether deeper anatomical suppression translates into improved clinical outcomes or influences the trajectory of macular atrophy. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Impact of faricimab and high-dose aflibercept on treatment demand in a tertiary ophthalmic centre in Norway. (PubMed, Acta Ophthalmol) - "The introduction of faricimab and high-dose aflibercept was associated with reduced per-patient treatment intensity, while the treated population continued to increase. Longer-acting anti-VEGF drugs may reduce pressure on retinal services by lowering injection frequency; however, their introduction was associated with higher overall costs."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Adoption patterns of anti-vascular endothelial growth factor therapies in retinal disease. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Real-world adoption of anti-VEGF therapies differs markedly across retinal diseases and agents. Aflibercept demonstrated sustained long-term use, while faricimab showed rapid early uptake. Changes in agent-specific utilization occurred alongside substantial growth in the absolute number of treated patients over the study period, underscoring the importance of interpreting drug-specific trajectories in the context of overall treatment activity."

Journal • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Understanding anti-vascular endothelial growth factor medications: chemical properties, costs, and side effects. (PubMed, J Med Life) - "This narrative review addressed the fact that the pharmacological properties, safety profiles, and cost-effectiveness of the currently marketed anti-VEGF intravitreal agents (i.e. bevacizumab, ranibizumab, aflibercept, brolucizumab, pegaptanib, and recently faricimab) differ and therefore, each of these agents, have their own unique molecular structure, target specificity, duration of action in the eye, and systemic circulation, each of which will affect the dosing intervals and treatment burden as well as the safety and adverse events associated with each drug. While anti-VEGF therapies are highly effective, the outcomes regarding safety, efficacy, and cost depend heavily on the study design and reflect the actual treatment paradigm and continuum of care within the healthcare system. The various attributes of agents should help personalize a patient's treatment approach while also addressing potential challenges related to the safety, efficacy, and longevity of..."

Adverse events • Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular Edema. (PubMed, Ophthalmol Ther) - P3 | "Greater IRF volume reduction during the first 3 months of treatment was associated with improved long-term outcomes in DME. These data may inform discussions between physicians and their patients when discussing long-term anatomic/functional outcomes of treatment."

Journal • Diabetic Macular Edema • Ophthalmology

Congestive heart failure and other cardiac adverse events after intravitreal anti-VEGF therapy: a systematic review and meta-analysis. (PubMed, Can J Ophthalmol) - "CHF and other AEs after intravitreal anti-VEGF therapy were uncommon in RCTs and comparable across agents. The aflibercept-sham CHF signal was based on limited evidence and should be interpreted cautiously."

Adverse events • Journal • Retrospective data • Age-related Macular Degeneration • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetic Macular Edema • Heart Failure • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Ischemic occlusive retinal vasculitis after intravitreal faricimab (Vabysmo®) injection in a patient with pachychoroid disease (PubMed, J Fr Ophtalmol) - No abstract available

Journal • Ocular Inflammation • Ophthalmology • Vasculitis

Real-world outcomes of faricimab in treatment-naïve diabetic macular edema: The Middle East perspective. (PubMed, Saudi J Ophthalmol) - "The findings suggest faricimab conferred visual and anatomical improvements in a heterogeneous group of patients with DME in real-world Middle East settings. Further real-world studies are essential to confirm long-term safety and effectiveness in clinical practice."

Journal • Real-world evidence • Diabetic Macular Edema • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders

Choroidal Vascular Remodeling After Loading Injections of Faricimab in Diabetic Macular Edema. (PubMed, Transl Vis Sci Technol) - "These findings suggest that faricimab may contribute to choroidal vascular remodeling in addition to resolving retinal fluid. This study shows that observed associations in imaging biomarkers after faricimab loading, such as SFCT and CVI, may provide additional clinical insights for individualized patient assessment in real-world settings, supporting the use of choroidal imaging as a complementary tool for managing diabetic macular edema."

Journal • Retrospective data • Diabetic Macular Edema • Ophthalmology

Early Macular Leakage Resolution Is Associated with Extended Faricimab Dosing in Retinal Vein Occlusion: A BALATON/COMINO Post Hoc Analysis. (PubMed, Ophthalmol Ther) - P3 | "ML resolution at week 24 was associated with extended faricimab dosing intervals and improved vision at week 68 in patients with RVO in the BALATON/COMINO clinical trials."

Journal • Retrospective data • Retinal Vein Occlusion

Molecular Determinants of Intravitreal Anti-VEGF Durability: Drug Architecture, Intraocular Pharmacokinetics, Target Biology and Treatment Resistance. (PubMed, Int J Mol Sci) - "Trial evidence for ranibizumab, aflibercept, conbercept, brolucizumab and faricimab shows that extended dosing can arise from greater starting exposure, altered binding architecture or pathway expansion without a proportionate change in intrinsic ocular half-life. We propose that durability be defined as a time-to-threshold phenotype integrating active target-site exposure, biological demand, anatomical recurrence, all treatment-related procedures and safety. Standardised estimands, longitudinal human ocular sampling, spatial exposure methods and externally validated mechanism-informed models are needed to make molecular durability comparable and clinically actionable."

Journal • PK/PD data • Review • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Gene Therapies • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Faricimab in previously treated nAMD: Real-World Outcomes of a No-Loading-Dose Switching Protocol. (PubMed, Ophthalmologica) - "In previously treated nAMD patients, switching to faricimab without a loading dose achieved meaningful treatment interval extension, potentially reducing treatment burden without compromising efficacy."

Journal • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Wet Age-related Macular Degeneration

Real-World Dosing Intervals for Long-Acting Anti-VEGF Intravitreal Injection Therapies in nAMD and DME: Academy IRIS® Registry Analysis. (PubMed, J Ocul Pharmacol Ther) - "Extension of injection intervals to 16 weeks is greatly reduced in real-world experience compared with phase 3 clinical studies. This discrepancy could be explained by protocol-mandated restrictive rescue criteria used in the registration studies, allowing injection only after vision loss and significant fluid recurrence. Current longer-acting anti-VEGF medications offer an extension to only 5-12 weeks for most patients in the real world."

Journal • Real-world evidence • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

One-year real-world data of intravitreal faricimab in patients with pre-treated neovascular age-related macular degeneration. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Switching to faricimab in recalcitrant, heavily pretreated nAMD may yield meaningful structural improvements while stabilizing visual acuity."

Journal • Real-world evidence • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Faricimab in the Treatment of Retinal Disease: A Narrative Review. (PubMed, Cureus) - "This literature review synthesizes information from preclinical studies and randomized controlled trials. It focuses on the molecular reasoning behind the use of faricimab and the safety profile compared with anti-VEGF monotherapy."

Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Optic Nerve Head Cotton Wool Spots Mimicking Inflammatory Optic Neuropathy in Central Retinal Vein Occlusion. (PubMed, Cureus) - "Two months after intravitreal faricimab injection, macular edema resolved and visual acuity improved; however, as disc edema subsided, new large whitish nodular lesions emerged on the optic nerve head inferiorly, nasally, and superiorly, corresponding to hyperreflective deposits on OCT...The lesions resolved over several months without development of optic atrophy or collateral vessels, and final visual acuity returned to 20/20 with normal visual fields. This case highlights that large CWS on the optic nerve head in non-ischemic CRVO can closely mimic neuro-inflammatory or infiltrative processes and that multimodal imaging combined with multidisciplinary evaluation is essential to avoid misdiagnosis and unnecessary treatment."

Journal • Cardiovascular • Diabetes • Diabetic Retinopathy • Dyslipidemia • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Macular Edema • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders • Retinal Vein Occlusion • Rheumatoid Arthritis • Rheumatology • Vasculitis

Faricimab in neovascular age-related macular degeneration: aqueous humor cytokine profiling and biomarker correlations. (PubMed, Front Med (Lausanne)) - "IP-10 may serve as a potential correlative biomarker linked to subclinical capillary rarefaction. Future studies should explore combined anti-IP-10 therapy or extended dosing intervals to preserve foveal vasculature while maintaining anti-leakage efficacy."

Biomarker • Journal • Age-related Macular Degeneration • Cataract • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • HGF • IFNG

Short-term morphological and functional outcomes of intravitreal faricimab for chorioretinal disorders: a real-world study in a Chinese population. (PubMed, Front Med (Lausanne)) - "In this short-term real-world study comprising three exploratory disease-specific cohorts of Chinese patients, faricimab was associated with favorable anatomical and functional outcomes and was well tolerated, with the most pronounced benefit in treatment-naïve nAMD eyes. Responses in DME and RVO-ME were more variable and appeared to be influenced by prior treatment history; these subgroup analyses were exploratory, and larger prospective studies are warranted."

Journal • Real-world evidence • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Occlusive Retinal Vasculitis after Intravitreal Faricimab. (PubMed, Ophthalmology) - No abstract available

Journal • Ocular Inflammation • Vasculitis

Two-year real-world effectiveness of faricimab after treatment switch in neovascular age-related macular degeneration. (PubMed, Int J Retina Vitreous) - "Switching to faricimab in previous treated nAMD patients enabled meaningful extension of TI over 2 years while maintaining stable visual acuity. These findings support faricimab as an effective strategy to reduce treatment burden in patients who are difficult to extend with prior anti-VEGF therapies."

Journal • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration